Forte Biosciences, Inc. (FBRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 7M 14M 21M FY18: 18M FY19: 36K FY18 FY19

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-75M -50M -25M 0 25M 50M 75M FY24: -36.6M FY25: -70.7M FY24 FY25

Net Income Annual

-75M -50M -25M 0 25M 50M 75M FY24: -35.5M FY25: -69.4M FY24 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY24: -30.7M FY25: -50.9M FY24 FY25

Free Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY24: -30.8M FY25: -51M FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 6M 12M 18M FY21: 14M FY22: 17.4M FY21 FY22

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q3 '24: -16.30 Q4 '24: -12.17 Q1 '25: -9.51 Q2 '25: -3.69 Q3 '25: -0.14 Q4 '25: -4.77 Q1 '26: -4.64 Q2 '26: -4.65 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.